Findings of research misconduct have been made against Shaker Mousa, Ph.D., M.B.A., FACC, FACB (Respondent), who was a Professor, Chairman, and Executive Vice President of the Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences (ACPHS). Respondent engaged in research misconduct in research supported by U.S. Public Health Service (PHS) funds, specifically National Cancer Institute (NCI), National Institutes of Health (NIH), grant R21 CA135245 and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, grant R01 DK052798. The administrative actions, including supervision for a period of four (4) years, were implemented beginning on May 15, 2024, and are detailed below.
A formal finding of research misconduct under 42 CFR part 93 (HHS) or equivalent agency policy. The respondent was found to have engaged in fabrication, falsification, or plagiarism of research data. The federal grant funds involved are typically identified in the FR notice, along with the administrative actions (debarment, supervised research, manuscript correction or retraction requirements).